Login / Signup

Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System.

Emily Jane WooAdamma Mba-JonasAlisha ThomasBethany BaerBrendan F DayYeowon KimMargarita Gomez-LorenzoNarayan Nair
Published in: Pharmacoepidemiology and drug safety (2022)
Life-threatening or fatal TEEs have been reported after Ad.26.COV2.S, including bilateral massive pulmonary embolism or other severe clot burden.
Keyphrases
  • pulmonary embolism
  • sars cov
  • respiratory syndrome coronavirus
  • adverse drug
  • coronavirus disease
  • inferior vena cava
  • atrial fibrillation
  • case report
  • emergency department
  • drug induced